Last reviewed · How we verify
Regular use of any other antidepressant — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Regular use of any other antidepressant (Regular use of any other antidepressant) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Regular use of any other antidepressant TARGET | Regular use of any other antidepressant | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Regular use of any other antidepressant CI watch — RSS
- Regular use of any other antidepressant CI watch — Atom
- Regular use of any other antidepressant CI watch — JSON
- Regular use of any other antidepressant alone — RSS
Cite this brief
Drug Landscape (2026). Regular use of any other antidepressant — Competitive Intelligence Brief. https://druglandscape.com/ci/regular-use-of-any-other-antidepressant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab